mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2024-3-14-24mrj-1584Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL INVESTIGATIONSОпыт применения олокизумаба у пациентов с воспалительным фенотипом остеоартритаOlokizumab in patients with inflammatory phenotype of osteoarthritis, treatment experiencehttps://orcid.org/0000-0002-6068-3080ЛилаА. М.LilaA. M.

кафедра ревматологии

115522; Каширское шоссе, 34А; 125993; ул. Баррикадная, 2/1, стр. 1; Москва

115522; 34A, Kashirskoe Shosse; 125993; 2/1, Barrikadnaya Street, Build. 1; Moscow

https://orcid.org/0000-0001-7017-0898АлексееваЛ. И.AlekseevaL. I.

кафедра ревматологии

115522; Каширское шоссе, 34А; 125993; ул. Баррикадная, 2/1, стр. 1; Москва

115522; 34A, Kashirskoe Shosse; 125993; 2/1, Barrikadnaya Street, Build. 1; Moscow

https://orcid.org/0000-0001-8218-3223ТаскинаЕ. А.TaskinaE. A.

Елена Александровна Таскина

115522; Каширское шоссе, 34А; Москва

 Elena Aleksandrovna Taskina

115522; 34A, Kashirskoe Shosse; Moscow

braell@mail.ruhttps://orcid.org/0000-0001-8732-2720КашевароваН. Г.KashevarovaN. G.

115522; Каширское шоссе, 34А; Москва

115522; 34A, Kashirskoe Shosse; Moscow

https://orcid.org/0000-0003-4242-8278ШараповаЕ. П.SharapovaE. P.

115522; Каширское шоссе, 34А; Москва

115522; 34A, Kashirskoe Shosse; Moscow

https://orcid.org/0000-0001-8130-5081СтребковаЕ. А.StrebkovaE. A.

115522; Каширское шоссе, 34А; Москва

115522; 34A, Kashirskoe Shosse; Moscow

https://orcid.org/0000-0001-8562-6077СавушкинаН. М.SavushkinaN. M.

115522; Каширское шоссе, 34А; Москва

115522; 34A, Kashirskoe Shosse; Moscow

https://orcid.org/0000-0002-0447-4110ХальметоваА. Р.KhalmetovaA. R.

115522; Каширское шоссе, 34А; Москва

115522; 34A, Kashirskoe Shosse; Moscow

https://orcid.org/0000-0002-7179-8174НестеренкоВ. А.NesterenkoV. A.

115522; Каширское шоссе, 34А; Москва

115522; 34A, Kashirskoe Shosse; Moscow

https://orcid.org/0000-0003-3057-9175АвдееваА. С.AvdeevaA. S.

115522; Каширское шоссе, 34А; Москва

115522; 34A, Kashirskoe Shosse; Moscow

https://orcid.org/0000-0001-7501-9185СамаркинаЕ. Ю.SamarkinaE. Yu.

115522; Каширское шоссе, 34А; Москва

115522; 34A, Kashirskoe Shosse; Moscow

https://orcid.org/0000-0001-6404-0042ДиатроптовМ. Е.DiatroptovM. E.

115522; Каширское шоссе, 34А; Москва

115522; 34A, Kashirskoe Shosse; Moscow

https://orcid.org/0000-0003-1852-1798АлексееваО. Г.AlekseevaO. G.

115522; Каширское шоссе, 34А; Москва

115522; 34A, Kashirskoe Shosse; Moscow

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation2024130620241831424Copyright © Лила А.М., Алексеева Л.И., Таскина Е.А., Кашеварова Н.Г., Шарапова Е.П., Стребкова Е.А., Савушкина Н.М., Хальметова А.Р., Нестеренко В.А., Авдеева А.С., Самаркина Е.Ю., Диатроптов М.Е., Алексеева О.Г., 20242024Лила А.М., Алексеева Л.И., Таскина Е.А., Кашеварова Н.Г., Шарапова Е.П., Стребкова Е.А., Савушкина Н.М., Хальметова А.Р., Нестеренко В.А., Авдеева А.С., Самаркина Е.Ю., Диатроптов М.Е., Алексеева О.Г.Lila A.M., Alekseeva L.I., Taskina E.A., Kashevarova N.G., Sharapova E.P., Strebkova E.A., Savushkina N.M., Khalmetova A.R., Nesterenko V.A., Avdeeva A.S., Samarkina E.Y., Diatroptov M.E., Alekseeva O.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/1584

   Цель исследования – изучить эффективность и безопасность применения олокизумаба (ОКЗ) у больных остеоартритом (ОА) коленного сустава (КС) с синовитом, постоянной болью и неэффективностью, предшествующей консервативной терапии.

   Материал и методы

   Материал и методы. В исследование включено 15 пациентов с ОА КС II–III стадии, соответствовавших критериям ACR, у которых отмечались боль 50 мм по визуальной аналоговой шкале (ВАШ), синовит и неэффективность терапии. Возраст пациентов варьировался от 54 до 75 лет, длительность заболевания – от 1 года до 23 лет. Длительность исследования составила 12 нед, в течение которых пациенты получили 3 подкожные инъекции ОКЗ в дозе 64 мг. Эффективность лечения оценивали по динамике интенсивности боли по ВАШ; индексов WOMAC и KOOS; значений опросников невропатической боли DN4 и качества жизни EQ-5D. Дополнительно учитывали общую оценку состояния здоровья пациента (ОСЗП) по ВАШ, оценку эффективности лечения врачом и пациентом, потребность в нестероидных противовоспалительных препаратах (НПВП). Всем пациентам проводилось лабораторное обследование.

   Результаты и обсуждение. На фоне терапии отмечены выраженное уменьшение интенсивности боли по ВАШ, статистически значимое улучшение индексов KOOS и WOMAC (p < 0,05), качества жизни по опроснику EQ-5D и ОСЗП. Пациенты и врачи высоко оценили результаты лечения: улучшение и значительное улучшение зарегистрировано в 92,3 % случаев. У 4 больных выявлены неблагоприятные явления, что в 2 случаях послужило поводом для отмены ОКЗ и прекращения участия в исследовании. На фоне лечения ОКЗ наблюдались статистически значимое снижение уровня СРБ и СОЭ, повышение концентрации интерлейкина 6 (p = 0,003), COMP (р = 0,03) и PIINP (р = 0,01).

   Заключение

   Заключение. Полученные результаты свидетельствуют о значимом симптоматическом и противовоспалительном эффекте ОКЗ у пациентов с воспалительным фенотипом ОА.

   Objective

   Objective: to investigate the efficacy and safety of olokizumab (OKZ) in patients with knee osteoarthritis (OA) with synovitis, persistent pain and ineffectiveness of previous conservative therapy.

   Material and methods

   Material and methods. The study included 15 patients with stage II–III knee OA who fulfilled the ACR criteria and had pain ≥50 mm on a visual analogue scale (VAS), synovitis and treatment failure. The age of patients ranged from 54 to 75 years; the duration of the disease was from 1 to 23 years. The duration of the study was 12 weeks, during which the patients received 3 subcutaneous injections of OKZ at a dose of 64 mg. The effectiveness of the treatment was assessed by the dynamics of pain intensity according to VAS, WOMAC and KOOS indices, the values of the DN4 questionnaire and the quality of life according to EQ-5D. In addition, the general assessment of the patient's health (GHA) according to VAS, the assessment of treatment efficacy by doctor and patient and the need for non-steroidal anti-inflammatory drugs (NSAIDs) were considered. All patients underwent laboratory testing.

   Results and discussion. During treatment, there was a significant decrease in pain intensity according to VAS, a statistically significant improvement in the KOOS and WOMAC indices (p<0.05), quality of life according to the EQ-5D questionnaire and GHA. Patients and doctors rated the treatment results very positively: an improvement or significant improvement was observed in 92.3% of cases. Adverse events were identified in 4 patients, which in 2 cases served as the reason for discontinuation of OKZ treatment and termination of participation in the study. During treatment with OKZ, a statistically significant decrease in CRP and ESR values, an increase in the concentration of interleukin 6 (p = 0.003), COMP (p = 0.03) and PIINP (p = 0.01) were observed.

   Conclusion

   Conclusion. The results obtained suggest a significant symptomatic and anti-inflammatory effect of OKZ in patients with the inflammatory phenotype of OA.

остеоартритвоспалительный фенотипинтерлейкин 6олокизумабosteoarthritisinflammatory phenotypeinterleukin 6olokizumabСтатья подготовлена в рамках научно-исследовательской работы, государственное задание № 1021051403074-2. Исследование не имело спонсорской поддержкиThe article was prepared within the framework of research work, government task № 1021051403074-2. The investigation has not been sponsoredReferencesGBD 2021 Osteoarthritis Collaborators. Global, regional, and national burden of osteoarthritis, 1990-2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023 Aug 21;5(9):e508-e522. doi: 10.1016/S2665-9913(23)00163-7.GBD 2021 Osteoarthritis Collaborators. Global, regional, and national burden of osteoarthritis, 1990-2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023 Aug 21;5(9):e508-e522. doi: 10.1016/S2665-9913(23)00163-7.Muthu S. Osteoarthritis, an old wine in a new bottle! World J Orthop. 2023 Jan 18;14(1): 1-5. doi: 10.5312/wjo.v14.i1.1.Muthu S. Osteoarthritis, an old wine in a new bottle! World J Orthop. 2023 Jan 18;14(1): 1-5. doi: 10.5312/wjo.v14.i1.1.Мазуров ВИ, Лила АМ, Алексеева ЛИ и др. Мультиморбидность при остеоартрите и плейотропные эффекты симптоматических средств замедленного действия. Резолюция международного мультидисциплинарного совета экспертов. Современная ревматология. 2023;17(5):123-131. doi: 10.14412/1996-7012-2023-5-123-131.Mazurov VI, Lila AM, Alekseeva LI, et al. Multimorbidity in osteoarthritis and pleiotropic effects of slow-acting symptomatic drugs. Resolution of the multidisciplinary International Expert Council. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2023;17(5):123-131. (In Russ.). doi: 10.14412/1996-7012-2023-5-123-131.Sanchez-Lopez E, Coras R, Torres A, et al. Synovial inflammation in osteoarthritis progression. Nat Rev Rheumatol. 2022 May;18(5): 258-275. doi: 10.1038/s41584-022-00749-9.Sanchez-Lopez E, Coras R, Torres A, et al. Synovial inflammation in osteoarthritis progression. Nat Rev Rheumatol. 2022 May;18(5): 258-275. doi: 10.1038/s41584-022-00749-9.Herrero-Beaumont G, Roman-Blas JA, Bruyere O, et al. Clinical settings in knee osteoarthritis: Pathophysiology guides treatment. Maturitas 2017 Feb:96:54-57. doi: 10.1016/j.maturitas.2016.11.013.Herrero-Beaumont G, Roman-Blas JA, Bruyere O, et al. Clinical settings in knee osteoarthritis: Pathophysiology guides treatment. Maturitas 2017 Feb:96:54-57. doi: 10.1016/j.maturitas.2016.11.013.Mathiessen A, Conaghan PG. Synovitis in osteoarthritis: current understanding with therapeutic implications. Arthritis Res Ther. 2017 Feb 2;19(1):18. doi: 10.1186/s13075-017-1229-9.Mathiessen A, Conaghan PG. Synovitis in osteoarthritis: current understanding with therapeutic implications. Arthritis Res Ther. 2017 Feb 2;19(1):18. doi: 10.1186/s13075-017-1229-9.Calvet J, Berenguer-Llergo A, Orellana C, et al. Specific-cytokine associations with outcomes in knee osteoarthritis subgroups: breaking down disease heterogeneity with phenotyping. Arthritis Res Ther. 2024 Jan 11;26(1):19. doi: 10.1186/s13075-023-03244-y.Calvet J, Berenguer-Llergo A, Orellana C, et al. Specific-cytokine associations with outcomes in knee osteoarthritis subgroups: breaking down disease heterogeneity with phenotyping. Arthritis Res Ther. 2024 Jan 11;26(1):19. doi: 10.1186/s13075-023-03244-y.Dell'Isola A, Allan R, Smith SL, et al. Identification of clinical phenotypes in knee osteoarthritis : a systematic review of the literature. BMC Musculoskelet Disord. 2016 Oct 12;17(1):425. doi: 10.1186/s12891-016-1286-2.Dell'Isola A, Allan R, Smith SL, et al. Identification of clinical phenotypes in knee osteoarthritis : a systematic review of the literature. BMC Musculoskelet Disord. 2016 Oct 12;17(1):425. doi: 10.1186/s12891-016-1286-2.Henrotin Y. Osteoarthritis in year 2021: biochemical markers. Osteoarthritis Cartilage. 2022 Feb;30(2):237-248. doi: 10.1016/j.joca.2021.11.001. Epub 2021 Nov 16.Henrotin Y. Osteoarthritis in year 2021: biochemical markers. Osteoarthritis Cartilage. 2022 Feb;30(2):237-248. doi: 10.1016/j.joca.2021.11.001. Epub 2021 Nov 16.Angelini F, Widera P, Mobasheri A, et al. Osteoarthritis endotype discovery via clustering of biochemical marker data. Ann Rheum Dis. 2022 May;81(5):666-675. doi: 10.1136/annrheumdis-2021-221763.Angelini F, Widera P, Mobasheri A, et al. Osteoarthritis endotype discovery via clustering of biochemical marker data. Ann Rheum Dis. 2022 May;81(5):666-675. doi: 10.1136/annrheumdis-2021-221763.Li S, Cao P, Chen T, Ding C. Latest insights in disease-modifying osteoarthritis drugs development. Ther Adv Musculoskelet Dis. 2023 May 13:15:1759720X231169839. doi: 10.1177/1759720X231169839.Li S, Cao P, Chen T, Ding C. Latest insights in disease-modifying osteoarthritis drugs development. Ther Adv Musculoskelet Dis. 2023 May 13:15:1759720X231169839. doi: 10.1177/1759720X231169839.Vrouwe JPM, Burggraaf J, Kloppenburg M, Stuurman FE. Challenges and opportunities of pharmacological interventions for osteoarthritis: A review of current clinical trials and developments. Osteoarthr Cartil Open. 2021 Sep 8;3(4):100212. doi: 10.1016/j.ocarto.2021.100212.Vrouwe JPM, Burggraaf J, Kloppenburg M, Stuurman FE. Challenges and opportunities of pharmacological interventions for osteoarthritis: A review of current clinical trials and developments. Osteoarthr Cartil Open. 2021 Sep 8;3(4):100212. doi: 10.1016/j.ocarto.2021.100212.Лапкина НА, Баранов АА, Левшин НЮ и др. Динамика клинических проявлений и концентрации цитокинов у больных ревматоидным артритом на фоне терапии олокизумабом. Научно-практическая ревматология. 2023;61(4):475-484.Lapkina NA, Baranov AA, Levshin NYu, et al. Dynamics of clinical manifestations and cytokine concentrations in patients with rheumatoid arthritis on olokizumab therapy. Nauchno-prakticheskaya revmatologiya. 2023; 61(4):475-484. (In Russ.)Akeson G, Malemud CJ. A Role for Soluble IL-6 Receptor in Osteoarthritis. J Funct Morphol Kinesiol. 2017;2(3):27. doi: 10.3390/jfmk2030027. Epub 2017 Aug 2.Akeson G, Malemud CJ. A Role for Soluble IL-6 Receptor in Osteoarthritis. J Funct Morphol Kinesiol. 2017;2(3):27. doi: 10.3390/jfmk2030027. Epub 2017 Aug 2.Beekhuizen M, Gierman LM, van Spil WE, et al. An explorative study comparing levels of soluble mediators in control and osteoarthritic synovial fluid. Osteoarthritis Cartilage. 2013 Jul;21(7):918-22. doi: 10.1016/j.joca.2013.04.002. Epub 2013 Apr 15.Beekhuizen M, Gierman LM, van Spil WE, et al. An explorative study comparing levels of soluble mediators in control and osteoarthritic synovial fluid. Osteoarthritis Cartilage. 2013 Jul;21(7):918-22. doi: 10.1016/j.joca.2013.04.002. Epub 2013 Apr 15.Sohn DH, Sokolove J, Sharpe O, et al. Plasma proteins present in osteoarthritic synovial fluid can stimulate cytokine production via toll-like receptor 4. Arthritis Res Ther. 2012 Jan 8;14(1):R7. doi: 10.1186/ar3555.Sohn DH, Sokolove J, Sharpe O, et al. Plasma proteins present in osteoarthritic synovial fluid can stimulate cytokine production via toll-like receptor 4. Arthritis Res Ther. 2012 Jan 8;14(1):R7. doi: 10.1186/ar3555.Wang ZW, Chen L, Hao XR, et al. Elevated levels of interleukin-1beta, interleukin-6, tumor necrosis factoralpha and vascular endothelial growth factor in patients with knee articular cartilage injury. World J Clin Cases. 2019 Jun 6;7(11):1262-1269. doi: 10.12998/wjcc.v7.i11.1262.Wang ZW, Chen L, Hao XR, et al. Elevated levels of interleukin-1beta, interleukin-6, tumor necrosis factoralpha and vascular endothelial growth factor in patients with knee articular cartilage injury. World J Clin Cases. 2019 Jun 6;7(11):1262-1269. doi: 10.12998/wjcc.v7.i11.1262.Livshits G, Zhai G, Hart DJ et al. Interleukin-6 is a significant predictor of radiographic knee osteoarthritis: the Chingford Study. Arthritis Rheum 2009;60 (7):2037–45. doi: 10.1002/art.24598.Livshits G, Zhai G, Hart DJ et al. Interleukin-6 is a significant predictor of radiographic knee osteoarthritis: the Chingford Study. Arthritis Rheum 2009;60 (7):2037–45. doi: 10.1002/art.24598.Stannus O, Jones G, Cicuttini F, et al. Circulating levels of IL-6 and TNF-alpha are associated with knee radiographic osteoarthritis and knee cartilage loss in older adults. Osteoarthritis Cartilage. 2010 Nov;18(11):1441-7. doi: 10.1016/j.joca.2010.08.016. Epub 2010 Sep 16.Stannus O, Jones G, Cicuttini F, et al. Circulating levels of IL-6 and TNF-alpha are associated with knee radiographic osteoarthritis and knee cartilage loss in older adults. Osteoarthritis Cartilage. 2010 Nov;18(11):1441-7. doi: 10.1016/j.joca.2010.08.016. Epub 2010 Sep 16.Goekoop RJ, Kloppenburg M, Kroon HM, et al. Low innate production of interleukin-1beta and interleukin-6 is associated with the absence of osteoarthritis in old age. Osteoarthritis Cartilage. 2010 Jul;18(7):942-7. doi: 10.1016/j.joca.2010.03.016. Epub 2010 Apr 22.Goekoop RJ, Kloppenburg M, Kroon HM, et al. Low innate production of interleukin-1beta and interleukin-6 is associated with the absence of osteoarthritis in old age. Osteoarthritis Cartilage. 2010 Jul;18(7):942-7. doi: 10.1016/j.joca.2010.03.016. Epub 2010 Apr 22.Tsuchida AI, Beekhuizen M, Rutgers M, et al. Interleukin-6 is elevated in synovial fluid of patients with focal cartilage defects and stimulates cartilage matrix production in an in vitro regeneration model. Arthritis Res Ther. 2012 Dec 3;14(6):R262. doi: 10.1186/ar4107.Tsuchida AI, Beekhuizen M, Rutgers M, et al. Interleukin-6 is elevated in synovial fluid of patients with focal cartilage defects and stimulates cartilage matrix production in an in vitro regeneration model. Arthritis Res Ther. 2012 Dec 3;14(6):R262. doi: 10.1186/ar4107.Tsuchida AI, Beekhuizen M, `t Hart MC, et al. Cytokine profiles in the joint depend on pathology, but are different between synovial fluid, cartilage tissue and cultured chondrocytes. Arthritis Res Ther. 2014 Sep 26;16(5):441. doi: 10.1186/s13075-014-0441-0.Tsuchida AI, Beekhuizen M, `t Hart MC, et al. Cytokine profiles in the joint depend on pathology, but are different between synovial fluid, cartilage tissue and cultured chondrocytes. Arthritis Res Ther. 2014 Sep 26;16(5):441. doi: 10.1186/s13075-014-0441-0.Guerne PA, Zuraw BL, Vaughan JH, et al. Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis. J Clin Invest. 1989 Feb;83(2): 585-92. doi: 10.1172/JCI113921.Guerne PA, Zuraw BL, Vaughan JH, et al. Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis. J Clin Invest. 1989 Feb;83(2): 585-92. doi: 10.1172/JCI113921.Bondeson J, Wainwright SD, Lauder S, et al. The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritis. Arthritis Res Ther. 2006;8(6): R187. doi: 10.1186/ar2099.Bondeson J, Wainwright SD, Lauder S, et al. The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritis. Arthritis Res Ther. 2006;8(6): R187. doi: 10.1186/ar2099.Nguyen HN, Noss EH, Mizoguchi F, et al. Autocrine loop involving IL-6 family member LIF, LIF receptor, and STAT4 drives sustained fibroblast production of inflammatory mediators. Immunity. 2017 Feb 21; 46(2):220-232. doi: 10.1016/j.immuni.2017.01.004.Nguyen HN, Noss EH, Mizoguchi F, et al. Autocrine loop involving IL-6 family member LIF, LIF receptor, and STAT4 drives sustained fibroblast production of inflammatory mediators. Immunity. 2017 Feb 21; 46(2):220-232. doi: 10.1016/j.immuni.2017.01.004.Wiegertjes R, van de Loo FAJ, Blaney Davidson EN. A roadmap to target interleukin-6 in osteoarthritis. Rheumatology (Oxford). 2020 Oct 1;59(10):2681-2694. doi:10.1093/rheumatology/keaa248.Wiegertjes R, van de Loo FAJ, Blaney Davidson EN. A roadmap to target interleukin-6 in osteoarthritis. Rheumatology (Oxford). 2020 Oct 1;59(10):2681-2694. doi:10.1093/rheumatology/keaa248.Distel E, Cadoudal T, Durant S, et al. The infrapatellar fat pad in knee osteoarthritis: an important source of interleukin-6 and its soluble receptor. Arthritis Rheum. 2009 Nov; 60(11):3374-7. doi: 10.1002/art.24881.Distel E, Cadoudal T, Durant S, et al. The infrapatellar fat pad in knee osteoarthritis: an important source of interleukin-6 and its soluble receptor. Arthritis Rheum. 2009 Nov; 60(11):3374-7. doi: 10.1002/art.24881.Pearson MJ, Herndler-Brandstetter D, Tariq MA, et al. IL-6 secretion in osteoarthritis patients is mediated by chondrocyte-synovial fibroblast cross-talk and is enhanced by obesity. Sci Rep. 2017 Jun 14;7(1):3451. doi: 10.1038/s41598-017-03759-w.Pearson MJ, Herndler-Brandstetter D, Tariq MA, et al. IL-6 secretion in osteoarthritis patients is mediated by chondrocyte-synovial fibroblast cross-talk and is enhanced by obesity. Sci Rep. 2017 Jun 14;7(1):3451. doi: 10.1038/s41598-017-03759-w.Richette P, Latourte A, Sellam J, et al. Efficacy of tocilizumab in patients with hand osteoarthritis: double blind, randomised, placebo-controlled, multicentre trial. Ann Rheum Dis. 2021 Mar;80(3):349-355. doi: 10.1136/annrheumdis-2020-218547.Richette P, Latourte A, Sellam J, et al. Efficacy of tocilizumab in patients with hand osteoarthritis: double blind, randomised, placebo-controlled, multicentre trial. Ann Rheum Dis. 2021 Mar;80(3):349-355. doi: 10.1136/annrheumdis-2020-218547.Sanchez Huerta JM, Galvez-Romero J, Lopez-Rodriguez W, Lopez A. UTILITY OF Tocilizumab in clinical manifestations of erosive osteoarthrosis of hands regional hospital issste puebla, Mεxico. Ann Rheum Dis. 2017; 76(Suppl 2):974. doi: 10.1136/annrheumdis-2017-eular.6483.Sanchez Huerta JM, Galvez-Romero J, Lopez-Rodriguez W, Lopez A. UTILITY OF Tocilizumab in clinical manifestations of erosive osteoarthrosis of hands regional hospital issste puebla, Mεxico. Ann Rheum Dis. 2017; 76(Suppl 2):974. doi: 10.1136/annrheumdis-2017-eular.6483.Kretsos K, Golor G, Jullion A, et al. Safety and pharmacokinetics of olokizumab, an anti-IL-6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I study. Clin Pharmacol Drug Dev. 2014 Sep;3(5):388-95. doi: 10.1002/cpdd.121. Epub 2014 May 26.Kretsos K, Golor G, Jullion A, et al. Safety and pharmacokinetics of olokizumab, an anti-IL-6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I study. Clin Pharmacol Drug Dev. 2014 Sep;3(5):388-95. doi: 10.1002/cpdd.121. Epub 2014 May 26.

The authors declare that there are no conflicts of interest present.